ArticleCancer medicine2016
CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- JUNB and JUND in Urological Cancers: A Literature Review.Current issues in molecular biology · 2025Review
- Association of HLA-DRA expression with prognosis and tumor microenvironment in clear cell renal cell carcinoma.Scientific reports · 2025Article
- Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention.Theranostics · 2025Review
- The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy.European journal of immunology · 2024Review
- Immune analysis of urine and plasma samples from patients with clear cell renal cell carcinoma.Oncology letters · 2024Article
- The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review.European journal of medical research · 2024Review
- Article
- The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.Biomarker research · 2023Review
- A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.Translational cancer research · 2023Article
- The Adipocyte-Macrophage Relationship in Cancer: A Potential Target for Antioxidant Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- JunB: a paradigm for Jun family in immune response and cancer.Frontiers in cellular and infection microbiology · 2023Review
- The generation, activation, and polarization of monocyte-derived macrophages in human malignancies.Frontiers in immunology · 2023Review
- Anti-inflammatory effect of green photobiomodulation in human adipose-derived mesenchymal stem cells.Lasers in medical science · 2022Article
- ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.Cancer science · 2022Article
- MCP-1 targeting: Shutting off an engine for tumor development.Oncology letters · 2022Review
- Key chemokines direct migration of immune cells in solid tumors.Cancer gene therapy · 2022Review
- The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma.Frontiers in immunology · 2022Review
- Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported that the pVHL-atypical PKC-JunB pathway contributed to promotion of cell invasiveness and angiogenesis in clear cell renal cell carcinoma (ccRCC), and we detected chemokine (C-C motif) ligand-2 (CCL2) as one of downstream effectors of JunB. CCL2 plays a critical role in tumorigenesis in other types of cancer, but its role in ccRCC remains unclear. In this study, we investigated the roles and therapeutic potential of CCL2 in ccRCC. Immunohistochemical analysis of CCL2 expression for ccRCC specimens showed that upregulation of CCL2 expression correlated with clinical stage, overall survival, and macrophage infiltration. For functional analysis of CCL2 in ccRCC cells, we generated subclones of WT8 cells that overexpressed CCL2 and subclones 786-O cells in which CCL2 expression was knocked down. Although CCL2 expression did not affect cell proliferation in vitro, CCL2 overexpression enhanced and CCL2 knockdown suppressed tumor growth, angiogenesis, and macrophage infiltration in vivo. We then depleted macrophages from tumor xenografts by administration of clodronate liposomes to confirm the role of macrophages in ccRCC. Depletion of macrophages suppressed tumor growth and angiogenesis. To examine the effect of inhibiting CCL2 activity in ccRCC, we administered CCL2 neutralizing antibody to primary RCC xenografts established from patient surgical specimens. Inhibition of CCL2 activity resulted in significant suppression of tumor growth, angiogenesis, and macrophage infiltration. These results suggest that CCL2 is involved in angiogenesis and macrophage infiltration in ccRCC, and that CCL2 could be a potential therapeutic target for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.